time to dialysis of 1.2, 6.5 and >10 years, respectively. In contrast, interstitial fibrosis was of less value as a predictor of disease progression in a subset of cases that included patients over the age of 70 and those with diabetic nephropathy on biopsy. Surprisingly, 13.9% of patients with normal renal function had 25-49% fibrosis and 5% had more than 50% fibrosis on biopsy, and 5 years after undergoing biopsy 21% of patients with >50% fibrosis still remained dialysis free. Conclusion: Renal fibrosis is an imperfect prognostic indicator for the development of ESRD and caution should be exercised in applying it too rigidly, especially in elderly or diabetic patients.
the underlying pathology, guide therapy, and ascertain the degree of active (potentially reversible) and chronic (considered irreversible) changes [1] [2] [3] [4] [5] [6] [7] . Chronic renal damaged is characterized by a variety of morphological changes that are common findings in different renal diseases. In the glomerular compartment, the major modifications are mesangial expansion and glomerulosclerosis; in the tubulointerstitial compartment, the characteristic modifications are tubular atrophy, interstitial fibrosis, and a reduction in the number of capillaries [2, 4] . Although the majority of ESRD patients in the United States have primary or secondary forms of glomerular disease, studies have suggested that it is actually the extent of accompanying histologic injury in the tubulointerstitium that correlates best with renal function decline [1, [5] [6] [7] [8] [9] [10] [11] [12] . Strictly applied, finding advanced fibrosis on renal biopsy might limit the use of beneficial but potentially toxic treatments based on the assumption of futility. In this study, we assessed the influence of other factors along with fibrosis as predictors of progression to dialysis and examined the predictive value of interstitial fibrosis in various patient groups. The amount of interstitial fibrosis was taken directly from the biopsy report. We intentionally did not validate the reported fibrotic index using morphometric techniques because in real life, clinical decisions are based on standard biopsy reports.
Methods
We performed a retrospective analysis of renal biopsies of adult patients at Boston University Medical Center (BUMC) between January 2001 and July 2012. All patients who underwent a successful kidney biopsy in this period were included in our initial evaluation, but we excluded 6 patients from subsequent analyses who had acute, reversible renal failure. The following data were collected from the patients' electronic medical record: demographic information, body mass index (BMI), urine protein-to-creatinine ratio, and serum creatinine. Glomerular filtration rate (GFR) was estimated using the 4 variable Modification of Diet in Renal Disease equation for patients who were less than 70 years of age [13] and Chronic Kidney Disease (CKD) Epidemiology Collaboration creatinine equation for patients older than 70 years. The presence or absence of comorbidities including hypertension (HTN), insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (DM), coronary artery disease (CAD), stroke, peripheral vascular disease (PVD), and autoimmune (AI) disease were noted. The following diseases were grouped under the AI category: vasculitis, lupus nephritis, immune complex glomerulonephritis, and post-infectious glomerulonephritis. Histological findings were noted from the biopsy report and included the degree of glomerulosclerosis, and the percentage of tubular atrophy and interstitial fibrosis. If there was more than one pathological finding on the biopsy, it was classified according to the most prevalent finding. Biopsy findings were categorized as having immunoglobulin A nephropathy, AI renal disease, diabetic nephropathy, or 'other nephropathy' (focal segmental glomerulosclerosis, hypertensive glomerulosclerosis, collapsing glomerulopathy, primary membranous nephropathy, thin basement membrane disease, interstitial nephritis, minimal change disease, or amyloidosis).
Serum creatinine at the time of biopsy and last creatinine available during the study period and/or time of dialysis initiation or death were collected.
The 2 primary end points of the study were initiation of dialysis and the time from kidney biopsy to the initiation of dialysis. We also evaluated a composite outcome of death without reaching dialysis or dialysis as a secondary outcome measure. Only 4 patients declined dialysis.
We described study sample characteristics via means and SDs for continuous variables and counts and percentages for categorical variables. Demographic factors, comorbidities, and laboratory measures were assessed as possible predictors of dialysis. We used a t test for continuous variables and Fisher's exact test for categorical variables to assess bivariate associations. Based on the current literature [14, 15] , we designed prediction models using clinical and biopsy variables to predict progression to dialysis. The following variables were included in the multivariable logistic model predicting the initiation of dialysis: demographic variables including age, sex, race, and BMI; comorbid conditions including IDDM, HTN, and composite of CAD, PVD, or stroke; laboratory variables at the time of the biopsy including GFR, creatinine, and proteinuria; biopsy findings including percentage of fibrosis, glomerulosclerosis, and nephropathy type. A parsimonious model was constructed using a backward elimination procedure with a 0.2 level to stay in the model. The model that includes fibrosis only was then evaluated. The discriminative ability of the models was described using C-statistic and receiver operating characteristic (ROC) curve. The models' fit was assessed using a Hosmer-Lemeshow test. The parsimonious model was compared to the fibrosis-only model using a likelihood ratio test. The effects were expressed via adjusted ORs with corresponding 95% CIs. The predicted probability of patients reaching dialysis based on the model including fibrosis only was assessed in various subgroups. A t test was used to compare predicted probability in patients who reached dialysis and patients who did not reach dialysis. We confirmed that there was a linear relationship between fibrosis and dialysis in our data (online suppl. table 6; for all online suppl. material, see www.karger.com/doi/10.1159/000449511). The amount of interstitial fibrosis was taken directly from the biopsy report prepared by an experienced, board-certified nephropathologist using standard diagnostic criteria [1] . We intentionally did not validate the reported fibrotic index using morphometric techniques because clinical decisions are based on a standard biopsy report.
Time to the initiation of dialysis was assessed in patients grouped based on the amount of fibrosis. Kaplan-Meier curves and log-rank test were used in unadjusted analyses. The proportional hazard Cox-regression model was used to adjust for potential confounders; these included the same variables as the dialysis prediction model. The effects were expressed via adjusted hazard ratios (HRs) with corresponding 95% CI. Analysis was performed using SAS 9.3 software (SAS Institute Inc., Cary, N.C., USA) and p value <0.05 was defined as statistically significant. 
Results

Patient Characteristics and Risk Factors for Dialysis
We identified 434 native kidney biopsies done at BUMC between 2001 and 2012. Baseline patient characteristics are summarized in table 1 . Over a median follow-up of 5.6 (0.46-11.82) years, 136 (31%) patients reached dialysis. Median time to dialysis was 0.86 (-0.03 to 10.6) years, including 6 patients who had dialysis immediately preceding the biopsy. During follow-up 15 (3.5%) patients died and median time to death was 2.18 years (0-10.4). The mean age at the time of biopsy was 45 ± 16. In our cohort, 42% of the patients were black, 22% were white, and 22% were Hispanic. The biopsies were performed in patients with various etiologies of chronic renal failure and a wide range of renal functions (creatinine 2.6 ± 2.6 mg/dl and GFR 57 ± 46 ml/min). The mean fibrosis at the time of biopsy was 31.2 ± 25.0% and mean glomerulosclerosis was 25.0 ± 24.5%. Patients who reached dialysis during the follow-up period were older (49 ± 16 vs. 43 ± 16 years) and dialysis was more likely to occur in male patients (38 vs. 24%). We noted a significant racial difference with the highest rate of dialysis in blacks (39%) and lower rates in whites (27%) and Hispanics (25%). Other clinical characteristics at baseline that were associated with a higher incidence of dialysis were HTN (41 vs. 10%), insulin-requiring DM (54 vs. 28%), cardiovascular disease (48 vs. 29%), higher levels of proteinuria (5.2 ± 4.4 vs. 3.3 ± 4.2 g), especially nephrotic range proteinuria (47 vs. 21%), higher creatinine (4.3 ± 3.2 vs. 1.8 ± 1.9 mg/dl), and lower GFR (29.4 ± 28.9 vs. 70.5 ± 46.6 ml/min). A history of AI disease carried a lower risk of dialysis (23.6 vs. 34.4%). As expected, more interstitial fibrosis (51.6 ± 23.7 vs. 21.9 ± 19.4%) and glomerular sclerosis (40.1 ± 28.4 vs. 18.1 ± 18.8%) were associated with dialysis. Patients with extensive interstitial fibrosis on biopsy but normal renal function had a median glomerulosclerosis score of 30 (range 5.7-66.7) that was similar to patients who had CKD. In unadjusted analysis, FGG was significantly associated with progression to dialysis (p < 0.001) but when adjusting for other factors FGG lost significance. Being on insulin treatment was a risk factor for dialysis, but being on oral agents was not.
The majority of the 172 patients who had a GFR >60 ml/min had less than 25% fibrosis on biopsy (139 or 81%), but surprisingly, 5% of these patients with near normal renal function had more than 50% fibrosis and 13.9% had 25-49% fibrosis ( table 2 ; fig. 1 ). As expected [16] , with decreasing GFR, there were more patients in the >50% Data are presented as mean ± SD, median (range), and n (%). p < 0.05 was considered significant. IgA = Immunoglobulin A; MDRD = Modification of Diet in Renal Disease; NIDDM = non-insulin dependent DM; CVA = cerebrovascular accident. 
Prediction of Dialysis
We designed a prediction model using demographic, clinical, and biopsy variables collected at the time of biopsy to predict progression to dialysis ( fig. 2 a, b ; online suppl. table 1a, b). The model included the following 6 factors: percentage of fibrosis, BMI, GFR, proteinuria, and diagnoses of HTN and IDDM ( fig. 2 a) . The model has very good discriminative ability (C = 0.879) and fit (Hosmer-Lemeshow p = 0.565). Interestingly, only GFR below 30 ml/min was predictive of future dialysis (online suppl. table 2a-c). The fibrosis alone model also had good characteristics with slightly lower discriminatory ability (C = 0.832, Hosmer-Lemeshow p = 0.174; fig. 2 b) . However, the 6-factor model was statistically superior (likelihood ratio test p < 0.001) to the fibrosis-alone model. ROCs for both models are shown in figure 2 a and b.
Interstitial Fibrosis and Dialysis in Different Patient Subgroups
We examined the association between the level of fibrosis and dialysis status in different clinical subgroups. It is critical to note that in all groups, the range of fibrosis was wide. While fibrosis was a powerful predictor of dialysis risk overall ( table 3 ), it was not predictive for some individuals. Regardless of the patients' diagnosis and demographics, there was a wide range of fibrosis observed in both the dialysis and non-dialysis groups. Some patients with 80% fibrosis on biopsy did not progress to ESRD ( table 3 ; 'no dialysis' range of fibrosis = 0-80%, table 1 ; interstitial fibrosis 0-80% in the 'no dialysis' group). There was an age-associated increase in the level of fibrosis in the patients who did not progress to dialysis ( table 3 ; 14.8 < 19.1 < 29.5 < 31.5%) indicating that moderate levels of fibrosis did develop with aging and this was not necessarily indicative of dialysis risk. While in all 3 younger groups who progressed to ESRD the mean level of fibrosis was similar (51-53.1%), the mean percent of fibrosis of 43.3% was lower in older patients (>70) who progressed to dialysis. There were large statistically significant differences in fibrosis level between dialysis and non-dialysis patients for the 3 younger age groups (p < 0.001). However, there was a much smaller difference in fibrosis level in the older patients and it did not reach statistical significance (p = 0.148). The difference between the dialysis versus non-dialysis groups of patients with diabetic nephropathy on biopsy also did not reach statistical significance (54.2 vs. 43.5%, p = 0.167).
Predictive Value of Interstitial Fibrosis
We examined the value of interstitial fibrosis as a sole predictor of dialysis in different patient subgroups (online suppl. table 3). In most groups, fibrosis was a strong predictor of progression. However, we found 3 subgroups of patients in which fibrosis did not predict progression. Fibrosis was better as a predictor of dialysis in the younger age groups, but with increasing age, the association became less strong. In older patients (>70 years), who represented 7.1% of our kidney biopsy cohort, fibrosis was not a statistically significant predictor of dialysis. Similarly, fibrosis was not a statistically significant predictor of dialysis in patients with diabetic nephropathy on biopsy or those receiving insulin therapy. In contrast, analysis of patients younger than 70 years who were non-diabetic showed that fibrosis is a good predictor of progression to ESRD both in our full-prediction model (C = 0.912) and in our fibrosis-only model (C = 0.866; online suppl. table 4).
Percentage of Interstitial Fibrosis and Time to Dialysis
We tested fibrosis as a predictor of time to dialysis ( table 4 a; fig. 3 , 4 ). Patients were categorized by the level of fibrosis into 3 groups with 0-24 (n = 199), 25-49 (n = 117), or >50 (n = 118) percent. As expected, the group with >50% fibrosis progressed to ESRD more rapidly that those with either 25-49 or 0-24% fibrosis with a median time to dialysis of 1.2 years compared to 6.5 and >10 years, respectively (p < 0.001; table 4 ; fig. 4 ). Note that 2 and 5 years after undergoing biopsy 42 and 21% of patients with >50% fibrosis still remained dialysis free ( table 4 a; fig. 4 ). Cox regression analysis showed that having >50 or 25-49% fibrosis significantly increased the risk of dialysis with HRs of 7.2 (95% CI 3.5-14.8) and 2.7 (95% CI 1.3-5.3), respectively, compared to less than 25% fi- ( table 4 b ). Lower BMI, GFR <30, and proteinuria >3.5 g were the best predictors of progression to dialysis along with percent fibrosis. We found similar results using dialysis or death as end point instead of dialysis (online suppl. table 5a, b and fig. 1 ).
Discussion
Our study highlights some of the limitations of using the level of interstitial fibrosis on renal biopsy to predict who will develop ESRD. Several studies have shown that fibrosis on biopsy is an index of functional renal impairment and a major determinant in the progression of CKD [1, 5, 6, [10] [11] [12] 17] . Our findings emphasize that although fibrosis performs well overall, it is of less value for a subset of individual cases. Regardless of patient characteristics, we observed a wide range of fibrosis both in patients who reached dialysis and who remained dialysis free. Surprisingly, some of the patients who had >80% fibrosis on the biopsy did not progress to ESRD during a 10-year followup period. Overreliance on fibrosis on biopsy may therefore erroneously identify patients as having advanced CKD at a time when interventions may still be effective. Extent of fibrosis is a determining factor in designing clinical trials and in kidney transplantation. Patients with extensive histologic evidence of renal scarring with the percentage of fibrosis exceeding 50% are excluded from clinical trials because they are considered poor candidates for the evaluation of the effect of the therapy. In particular, they are routinely excluded from trials using medications that are designed to modulate immune response and functionally important inflammatory nephritis [18] . However, our data demonstrate that 42 and 21% of these patients are dialysis free at years 2 and 5, respectively, suggesting that some of those patients might also benefit from treatment. Patients who would benefit from a kidney transplant may have to remain on the waitlist because kidneys with mild interstitial fibrosis are being rejected for transplantation [19] . Our study conducted in native kidneys is consistent with several studies in the transplant literature showing that a mild-to-moderate degree of fibrosis on time-zero biopsy does not necessarily predict worse graft function in living or deceased donor kidney transplantation [20] [21] [22] [23] .
To the best of our knowledge, this is the first study to identify specific patient groups where fibrosis does not perform well in predicting progression to ESRD: (1) in patients older than 70 years of age or (2) patients with diabetic nephropathy on biopsy. Our data show that aging leads to an increase in the level of fibrosis even in patients who do not progress to ESRD, making fibrosis a less reliable prognostic factor in the elderly. Age-associated glomerulosclerosis may in part explain the weaker correlation in the elderly patients. A previous study from 1991 with a large cohort of 488 patients with diabetic nephropathy had suggested that fibrosis correlates with progression to ESRD [24] . In contrast, in our cohort of 42 patients with diabetic nephropathy on biopsy, the level of interstitial fibrosis was not a reliable predictor of progression. One possible explanation for the divergent finding is the changing nature of diagnosis and treatment of patients with diabetic nephropathy. Patients with poorly controlled diabetes and other obvious microvascular complications are frequently not biopsied. As a result, we have a lower biopsy rate in these patients compared to other etiologies and this potentially could lead to sampling bias. Alternatively, the poor correlation between fibrosis and ESRD progression in our study could be because diabetic patients usually have some level of chronic vascular injury that can be patchy leading to variable levels of fibrosis in the tissue.
Another helpful clinical tool, in conjunction with predicting if a patient will progress to dialysis, is anticipating the amount of time a patient has until dialysis initiation ( table 4 a; fig. 3 , 4 ) . This data could be used in clinical practice to give a rough estimate of dialysis-free survival to our patients based on their level of fibrosis. In general, the group with more fibrosis progressed to ESRD more rapidly than those with less fibrosis, but again, individual variability was large regardless of biopsy diagnosis or patient characteristics.
We noted several expected findings that confirmed previous observations. Patients who reached dialysis during the follow-up period were older and more likely to be male. HTN, nephrotic range proteinuria, vascular disease, and worse renal function at the time of biopsy were all risk factors for dialysis. Being on insulin treatment was a risk factor for dialysis, but being on oral agents was not a risk factor, suggesting that easily controlled diabetics often do not progress to ESRD. History of AI diseases car- ried a lower risk of dialysis likely because these groups of pathologies are potentially treatable. All biopsies were read by one of our 2 pathologists; therefore, the pathological findings are internally consistent. In general, the reliability of pathologist-based estimates of fibrosis improves the likelihood that our findings can be accurately reproduced in other centers. Furthermore, because interstitial fibrosis is one of the common final pathways in all kidney diseases, the results of this study are widely applicable.
Another important strength of our study is that its conclusions carry across racial lines. Our patient population was diverse: 42% of the patients were black, 22% were white, and 22% were Hispanic. Renal disease disproportionately affects African-Americans; therefore, it is imperative to validate study findings in this population. Similar to previous studies we found that blacks were more likely to progress to ESRD regardless of their diagnosis.
Death rate was relatively low in our cohort. Only 15 (3.46%) patients died during the study period. The median time to death was 2.18 years. We speculate that very sick patients who died soon after presentation were not biopsied. The long duration of follow-up (median 5.6 years), large sample size, low rate of loss to follow-up, and availability of detailed medical history in electronic medical records are additional strengths.
In our cohort, a large proportion of renal biopsies were done at CKD stages 3-4 with mean creatinine of 2.6 ± 2.6 mg/dl. Most of these patients likely had renal impairment, proteinuria, or hematuria for a prolonged period of time before they were referred to a nephrologist and a biopsy was done.
The retrospective nature of this study is a limitation. Another potential limitation is that timing of the biopsy and dialysis initiation can be physician dependent and could contribute to lead time bias. In our opinion, in a university teaching hospital setting, nephrologists follow the same guidelines, so it is unlikely that provider variability had a large effect on renal outcome or timing of dialysis. Results for specific subgroups of patients were based on limited sample sizes and should be confirmed in a larger cohort. Last, our study results were derived from a single cohort and will require validation in an external cohort. While the inclusion of additional information in a predictive model resulted in statistically significant improvement in discriminatory ability, it is not clear whether this improvement is clinically relevant. How multiple predictors could be used simultaneously in clinical practice also warrants further study.
Our study identifies some of the limitations in establishing disease prognosis and progression from a kidney biopsy obtained at one point in the course of a chronic disease affected by sampling error. Development of a noninvasive technique such as transient elastography for liver fibrosis [25] [26] [27] [28] would be ideal for repeated, global assessment of renal fibrosis and to determine whether or not it correlates with functional deterioration. In the meantime, we should be cautious about the interpretation of renal fibrosis, especially in the elderly and those with diabetic nephropathy.
